Prostate cancer—highlights from American Society of Clinical Oncology virtual meeting 2020

doi:10.1016/j.ajur.2021.10.005

Asian Journal of Urology, 2022, 9 (3): 282-286 doi: 10.1016/j.ajur.2021.10.005

Editorial

Current Issue | Archive | Adv Search

Prostate cancer—highlights from American Society of Clinical Oncology virtual meeting 2020

Nora Naqos^a,*(

),Wafaa Kaikani^b

^aDepartment of Medical Oncology, Mohammed VI University Hospital of Marrakech, Morocco
^bDepartment of Medical Oncology, Casablanca Cancer Center, University Mohammed VI des Sciences de la Santé, Morocco

Abstract
Related Citation (0)

[1]	Shore N, Saad Fred, Cookson M, George D, Saltzstein D, Tutrone R, et al. Oral relugolix for androgen deprivation therapy in advanced prostate cancer. N Engl J Med 2020; 382: 2187e96.
[2]	Small E, Fred S, Chowdhury S, Oudard S, Hadaschik B, N Graff J, et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 2020; 38: 5516. https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.5516.
[3]	Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019; 380:1235e46. doi: 10.1056/NEJMoa1815671
[4]	Sternberg C, Fizazi K, Fred S, Shore N, De Giorgi U, Penson D, et al. Final overall survival (OS) from PROSPER: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castrationresistant prostate cancer (nmCRPC). J Clin Oncol 2020; 38.(suppl; abstr 5515). https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5515.
[5]	Jiang S, Terasawa E, Horton G, Ayyagari R, Waldeck R, Halabi S, et al. Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): matching-adjusted indirect comparisons. J Clin Oncol 2020; 38. (suppl; abstr 5561). https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5561.
[6]	Armstrong J, Szmulewitz Z, Petrylak P, Villers A, Azad A, Alcaraz A, et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial. J Clin Oncol 2019; 37:687. https://ascopubs.org/doi/10.1200/JCO.19.00799?url_verZZ39.88-2003&rfr_idZori:rid:crossref.org&rfr_datZcr_pub%20%200pubmed.
[7]	Shore N, Armstrong J, Szmulewitz Z, Petrylak P, Holzbeierlein J, Villers A, et al. Efficacy of enzalutamide (ENZA) t androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. J Clin Oncol 2020; 38:5547. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5547. doi: 10.1200/JCO.2020.38.15_suppl.5547
[8]	Sternberg C, Castellano D, De Bono JS, Fizazi K, Tombal BF, WÜlfing C, et al. Efficacy and safety in older patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study. J Clin Oncol 2020; 38 (suppl; abstr 5559). https://doi.org/10.1016/j.eururo.2021.06.021.
[9]	Tombal BF, Castellano D, Kramer G, Eymard JC, De Bono JS, Sternberg C, et al. Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide. J Clin Oncol 2020; 38:5569. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5569. doi: 10.1200/JCO.2020.38.15_suppl.5569
[10]	MorrisM, Carroll P, Probst S, Pouliot F, SapersteinL, SiegelB, et al. Prospective phase 2/3 multi-center study of 18F-DCFPyL PET/CTimaging in patients with prostate cancer: examination of diagnostic accuracy (OSPREY). J Clin Oncol 2018; 36:5092. https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS5092.
[11]	Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Jeffrey YC, et al. Impact of PSMA-targeted imaging with 18FDCFPyL-PET/CT on clinical management of patients (Pts) with biochemically recurrent (BCR) prostate cancer (PCa): results from a phase III, prospective, multicenter study (CONDOR). J Clin Oncol 2020; 38. suppl; abstr 5501). https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.5501.
[12]	Hofman M, Emmett L, Sandhu SK, Iravani A, Joshua A, Goh J, et al. TheraP: a randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603). J Clin Oncol 2020; 38 (suppl; abstr 5500). https://doi.org/10.1016/S0140-6736(21)00237-3.
[13]	Hoimes C, Graff J, Tagawa S, Hwang C, Kilari D, Ten Tije A, et al. KEYNOTE-199 cohorts (C) 4 and 5: phase II study of pembrolizumab (Pembro) plus enzalutamide (Enza) for enzaresistant metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020; 38:5543. https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.5543. doi: 10.1200/JCO.2020.38.15_suppl.5543
[14]	Yu E Y, Rodriguez J, Gravis G, Laguerre B, Arranz Arija J, Oudard S, et al. Pembrolizumab (Pembro) plus olaparib in patients (Pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A efficacy, safety, and biomarker results. J Clin Oncol 2020; 38:5544. https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.5544. doi: 10.1200/JCO.2020.38.15_suppl.5544